Sitagliptin (Symlin)
Mechanism of action: incretins, sush as glucagon-like peptide-1 (GLP-1), it is enhance glucose-dependent insulin secreation and exhibit other antihyperglycemic actions following their release into the circulation from the gut. BYETTA (exenatide injection) is a GLP-1 receptor agonist that enhances glucose-dependent insulin secreation, and slows gastric emptying.
Adverse reaction: hypoglycemia
Sitagliptin (Januvia)
Mechanism of action: it is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by JANUVIA, therapy increasing and prolonging the action of these hormones. Incretin
Mechanism of action: incretins, sush as glucagon-like peptide-1 (GLP-1), it is enhance glucose-dependent insulin secreation and exhibit other antihyperglycemic actions following their release into the circulation from the gut. BYETTA (exenatide injection) is a GLP-1 receptor agonist that enhances glucose-dependent insulin secreation, and slows gastric emptying.
Adverse reaction: hypoglycemia
Sitagliptin (Januvia)
Mechanism of action: it is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by JANUVIA, therapy increasing and prolonging the action of these hormones. Incretin